The researchers said a microbiome-based test could expand the number of individuals who are screened for the disease.
The firm has expansive plans, including a possible launch of 40 different types of tests. It currently plans to launch a liver function test in the US this summer.
The companies today launched four assays for the Chinese market for renal, liver, and cardiac testing for use on the Vitros 4600 and Vitros 5600 systems.
Genfit's assay will be deployed through Covance's central laboratories to validate its use to better identify and characterize patients with the liver disease.
The Massachusetts Institute of Technology spinout has created a new class of activity sensors that query the body and report back clinically relevant information.
Glycotest's biomarker test for detection of hepatocellular carcinoma calculates the amount of monosaccharide fucose that appears abnormally on specific serum glycoproteins.
Factors that may have led to the explosion in testing include more consultations between patients and general practitioners, and a fear among GPs of being sued.
Used with other clinical evidence, Siemen Healthineer's blood-based test aids clinicians in assessing the fibrosis stage of chronic liver disease.
The firm anticipates that in 2019 it will begin clinical trials for a comprehensive metabolic panel for use on its point-of-care platform.
The funding will be directed at conducting clinical trials for its technology based on activity sensors to detect human diseases and monitor drug responses.